Jove
Visualize
Contact Us

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

84
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
84
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

24
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
24
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.5K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.5K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.2K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.7K
The pathophysiology of pneumonia involves the following steps:
4.7K
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

219
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of Structured Tele-Critical Care Training and Its Impact on Clinician's Perceptions of Delivery of Care: A Survey-Based Pilot Study.

Critical care explorations·2025
Same author

Assessment of Posttransplant Bacteremia Caused by Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacteria Among Kidney Transplant Recipients.

Clinical transplantation·2024
Same author

Hepatitis B prophylaxis among recipients of a hepatitis B core antibody positive liver transplant.

Journal of the American Pharmacists Association : JAPhA·2023
Same author

Dengvaxia: the world's first vaccine for prevention of secondary dengue.

Therapeutic advances in vaccines and immunotherapy·2021
Same author

Weil's Disease in an HIV-Infected Patient.

Cureus·2021
Same author

Comparison of Student Pharmacists' Clinical Interventions by Semester During APPE Internal Medicine and Critical Care Rotations.

Journal of pharmacy practice·2020
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

1.4K

Eosinophilic pneumonia induced by ceftaroline.

Carrie L Griffiths1, Kristofer C Gutierrez, Renee D Pitt

  • 1Carrie L. Griffiths, Pharm.D., is Assistant Professor, Pharmacist, Wingate University School of Pharmacy (WUSOP), Wingate, NC, and Critical Care Clinical Pharmacist, Department of Pharmacy, Carolinas Medical Center, Charlotte, NC. Kristofer C. Gutierrez is Pharm.D. student; and Renee D. Pitt is Pharm.D. student, WUSOP. Roger D. Lovell, M.D., FACP, is Infectious Disease Physician and Clinical Professor, Department of Internal Medicine, University of North Carolina School of Medicine, Charlotte.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|February 19, 2014
PubMed
Summary

A patient developed eosinophilic pneumonia while being treated with ceftaroline for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Symptoms resolved after discontinuing ceftaroline and initiating methylprednisolone.

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.0K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K

Related Experiment Videos

Last Updated: May 3, 2026

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

1.4K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.0K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • A patient with a history of respiratory conditions was hospitalized with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia.
  • Initial antibiotic treatment with vancomycin and meropenem, followed by linezolid, was ineffective.

Observation:

  • The patient was switched to intravenous ceftaroline, a cephalosporin antibiotic effective against MRSA.
  • Within five days of ceftaroline treatment, the patient experienced respiratory distress and significant peripheral eosinophilia (40%).
  • Bronchoalveolar lavage confirmed pulmonary eosinophilia (13%), and imaging ruled out pulmonary embolism.

Findings:

  • Ceftaroline administration was associated with the development of drug-induced eosinophilic pneumonia.
  • Discontinuation of ceftaroline and initiation of intravenous methylprednisolone led to the resolution of eosinophilia and clinical improvement.

Implications:

  • This case highlights a potential adverse reaction to ceftaroline, specifically eosinophilic pneumonia.
  • Clinicians should consider ceftaroline-induced lung injury in patients presenting with respiratory symptoms and eosinophilia during treatment.
  • Prompt recognition and management, including drug cessation and corticosteroid therapy, are crucial for favorable outcomes.